Show simple item record

dc.contributor.convenorProf. Amos D. Korczynen_AU
dc.contributor.authorGriffiths, Lynen_US
dc.contributor.authorLea, Rodneyen_US
dc.contributor.authorColson, Natalieen_US
dc.contributor.authorQuinlan, Sharonen_US
dc.contributor.authorMacMillan, J.en_US
dc.date.accessioned2017-05-03T12:16:19Z
dc.date.available2017-05-03T12:16:19Z
dc.date.issued2009en_US
dc.date.modified2010-07-09T03:10:16Z
dc.identifier.urihttp://hdl.handle.net/10072/31773
dc.description.abstractMigraine is a severe neurological disorder that affects a significant proportion of the population. Prevalence estimates for the disorder vary between 12 and 25% depending on the population studied. The disorder has a significant genetic component showing high levels of familial aggregation. Although a number of genes involved in a rare and severe sub-type of migraine, termed familial hemiplegic migraine have been identified, the number and identity of all the genes involved in the more common types of migraine have yet to be defined. Genetic characterisation of migraine have implicated genomic regions on a number of chromosomes, including 1q, 4q, 5q, 6p, 11q, 14q, 15q, 17p, 18q, 19p and Xq. In addition, candidate gene association studies have identified several susceptibility variants that are implicated in the disorder. Neurotransmitter pathways have been the main focus of studies investigating the molecular mechanisms of the disorder. However vascular and hormonal triggers disturbances also occur in migraineurs, as highlighted by alterations in cerebral blood flow and hormonal triggers of migraine, particularly in women and hence factors affecting these functions may also be involved. This presentation will focus on migraine gene studies in our laboratory, including recent studies implicating dopamine beta hydroxylase and MTHFR functional variants, as well as presenting an overview of results from a recently completed clinical trial that involved genetic profiling in conjunction with a nutriceutical therapeutic treatment. These clinical trial results are very promising and highlight the potential importance of pharmacogenetic interventions in this disorder.en_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherComtecMeden_US
dc.publisher.urihttp://www.comtecmed.com/cony/2009/en_AU
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofconferencename3rd World Congress on Controversies in Neurology (CONy)en_US
dc.relation.ispartofconferencetitle3rd World Congress on Controversies in Neurology (CONy) Scientific Programmeen_US
dc.relation.ispartofdatefrom2009-10-10en_US
dc.relation.ispartofdateto2009-10-12en_US
dc.relation.ispartoflocationPrague, Czech Republicen_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchNeurosciences not elsewhere classifieden_US
dc.subject.fieldofresearchcode110999en_US
dc.titleGenetics of Migraine: Implications for novel treatmentsen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conference Publications (Extract Paper)en_US
dc.type.codeE - Conference Publicationsen_US
gro.facultyGriffith Health, School of Medical Scienceen_US
gro.date.issued2009
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record